General Information of Drug Therapeutic Target (DTT) (ID: TTS41ER)

DTT Name HUMAN cyclophilin A (CYPA)
Synonyms PPIA; Cyclophilin A; CyPA
Gene Name PPIA
Related Disease
Hepatitis virus infection [ICD-11: 1E50-1E51]
BioChemical Class
Cis-trans-isomerases
UniProt ID
PPIA_HUMAN
TTD ID
T98092
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
EC Number
EC 5.2.1.8
Sequence
MVNPTVFFDIAVDGEPLGRVSFELFADKVPKTAENFRALSTGEKGFGYKGSCFHRIIPGF
MCQGGDFTRHNGTGGKSIYGEKFEDENFILKHTGPGILSMANAGPNTNGSQFFICTAKTE
WLDGKHVVFGKVKEGMNIVEAMERFGSRNGKTSKKITIADCGQLE
Function Ppiases accelerate the folding of proteins. It catalyzes the cis-trans isomerization of proline imidic peptide bonds in oligopeptides.
KEGG Pathway
( )
( )
Reactome Pathway
Uncoating of the HIV Virion (R-HSA-162585 )
Budding and maturation of HIV virion (R-HSA-162588 )
Integration of provirus (R-HSA-162592 )
Early Phase of HIV Life Cycle (R-HSA-162594 )
Minus-strand DNA synthesis (R-HSA-164516 )
Plus-strand DNA synthesis (R-HSA-164525 )
Binding and entry of HIV virion (R-HSA-173107 )
Assembly Of The HIV Virion (R-HSA-175474 )
APOBEC3G mediated resistance to HIV-1 infection (R-HSA-180689 )
Calcineurin activates NFAT (R-HSA-2025928 )
Basigin interactions (R-HSA-210991 )
Neutrophil degranulation (R-HSA-6798695 )
Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation (R-HSA-8950505 )
Platelet degranulation (R-HSA-114608 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Alisporivir DMWMIRL Hepatitis C virus infection 1E51.1 Investigative [1], [2]
------------------------------------------------------------------------------------

References

1 Therapeutic options for the 2019 novel coronavirus (2019-nCoV). Nat Rev Drug Discov. 2020 Mar;19(3):149-150.
2 Coronaviruses - drug discovery and therapeutic options. Nat Rev Drug Discov. 2016 May;15(5):327-47.